---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-132302"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:39:35.156215+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC

## Summary
- 100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.
- 75% maintained PSA50 and 50% maintained PSA90 at ≥12 weeks.
- 50% ORR (4/8 RECIST-evaluable patients) with confirmed/unconfirmed partial responses.
- CRS and TRAEs primarily cycle 1, grade 1-2; MTD not yet reached.
- Two once-weekly step dose regimens identified for Phase 1b in pre-PLUVICTO 2L/3L patients.

## SEC filing metadata
- accession: 0000950170-24-132302
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024132302/0000950170-24-132302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024132302/janx-20241202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-132302
- JSON: https://secwatch.observer/filing/0000950170-24-132302.json
- Plain text: https://secwatch.observer/filing/0000950170-24-132302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.